| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
in Ovine Articular Chondrocytes1
Department of Medicine, Modbury Public Hospital (D.S., J.D.M.), Modbury 5092, South Australia, Australia; and the Cooperative Research Center for Tissue Growth and Repair, Child Health Research Institute, Womens and Childrens Hospital (D.S., T.E.R., D.A.B.), North Adelaide 5006, South Australia, Australia; and the Department of Veterans Affairs, Medical Center (D.L.A.), Seattle, Washington 98108
Address all correspondence and requests for reprints to: Damir Sunic, Department of Medicine, Modbury Public Hospital, Smart Road, Modbury 5092, South Australia, Australia.
Insulin-like growth factors (IGFs) contribute to the maintenance of the
cartilage matrix by stimulating proteoglycan synthesis. In contrast,
interleukin-1 (IL-1), an inflammatory cytokine, suppresses the
synthesis of proteoglycans. In pathological conditions the
chondrocytes responsiveness to IGF-I is decreased, and elevated
levels of IGF-binding proteins (IGFBPs) have been implicated as a
possible cause. The aim of this study was to investigate the effects of
IGF-I and IL-1 on IGFBP production by ovine articular chondrocytes
(OAC) and the roles of these IGFBPs in the regulation of proteoglycan
synthesis. As revealed by Western ligand and immunoblotting, OACs
secreted IGFBP-2 and a 24-kDa IGFBP in culture medium under basal
conditions. Exposure of the cells to IGF-I for 48 h resulted in
the appearance of IGFBP-5 in the medium. Des(13)IGF-I, an IGF-I
analog with reduced affinity for IGFBPs, also increased the level of
IGFBP-5, but to a lesser extent than IGF-I, whereas
LR3IGF-I, which has virtually no affinity for IGFBPs, had
no effect on IGFBP-5. Furthermore, IGFBP-5 underwent a time-dependent
limited proteolysis when incubated with OAC-conditioned medium,
degrading into 22- and 16-kDa fragments. The degradation of IGFBP-5 was
significantly inhibited by IGF-I, but not by des(13)IGF-I or
LR3IGF-I. Basic fibroblast growth factor, transforming
growth factor-ß, and platelet-derived growth factor had no effect on
OAC IGFBPs. However, IL-1
increased the IGFBP-5 level in a
dose-dependent manner, showing maximum activity at 200 U/ml.
Furthermore, IL-1
, but not IGF-I, induced IGFBP-5 messenger RNA
expression, as assessed by Northern blot analysis. Coincubation of
IGF-I with IL-1
resulted in a substantially increased IGFBP-5
protein level, suggesting a synergism between the mechanisms of action
of these two factors. Des(13)IGF-I and LR3IGF-I were 10
times more potent than IGF-I in stimulating proteoglycan synthesis,
indicating inhibition of IGF-I activity by endogenous IGFBPs. IL-1
reduced the IGF-I bioactivity, but had no effect on the activities of
the IGF-I analogs, thus implying that locally produced IGFBPs,
particularly IGFBP-5, which was substantially increased when IGF-I and
IL-1
were coincubated, mediated the reduction of the IGF-I activity.
Our results demonstrate that IGF-I and IL-1
synergistically increase
the level of IGFBP-5 in OAC by inhibiting the proteolysis and
stimulating the expression of IGFBP-5, respectively. Furthermore,
the attenuation of IGF-I-stimulated proteoglycan synthesis by IL-1
in OAC appears to be mediated by chondrocyte IGFBPs. We conclude that
locally produced IGFBPs, in particular IGFBP-5, may play a critical
role in the regulation of cartilage matrix degradation in inflammatory
and degenerative arthritides.
This article has been cited by other articles:
![]() |
A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights Endocr. Rev., February 1, 2007; 28(1): 20 - 47. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Granado, A I Martin, T Priego, A Lopez-Calderon, and M A Villanua Tumour necrosis factor blockade did not prevent the increase of muscular muscle RING finger-1 and muscle atrophy F-box in arthritic rats. J. Endocrinol., October 1, 2006; 191(1): 319 - 326. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. Lang, B. J. Krawiec, D. Huber, J. M. McCoy, and R. A. Frost Sepsis and inflammatory insults downregulate IGFBP-5, but not IGFBP-4, in skeletal muscle via a TNF-dependent mechanism Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2006; 290(4): R963 - R972. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Granado, T. Priego, A. I. Martin, M{a} A. Villanua, and A. Lopez-Calderon Ghrelin receptor agonist GHRP-2 prevents arthritis-induced increase in E3 ubiquitin-ligating enzymes MuRF1 and MAFbx gene expression in skeletal muscle Am J Physiol Endocrinol Metab, December 1, 2005; 289(6): E1007 - E1014. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Spicer Proteolytic Degradation of Insulin-Like Growth Factor Binding Proteins by Ovarian Follicles: A Control Mechanism for Selection of Dominant Follicles Biol Reprod, May 1, 2004; 70(5): 1223 - 1230. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yamagami, S. Yokoo, T. Mimura, and S. Amano Effects of TGF-{beta}2 on Immune Response-Related Gene Expression Profiles in the Human Corneal Endothelium Invest. Ophthalmol. Vis. Sci., February 1, 2004; 45(2): 515 - 521. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Dahlfors and H. J. Arnqvist Vascular Endothelial Growth Factor and Transforming Growth Factor-{beta}1 Regulate the Expression of Insulin-Like Growth Factor-Binding Protein-3, -4, and -5 in Large Vessel Endothelial Cells Endocrinology, June 1, 2000; 141(6): 2062 - 2067. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Boonyaratanakornkit, D. D. Strong, S. Mohan, D. J. Baylink, C. A. Beck, and T. A. Linkhart Progesterone Stimulation of Human Insulin-like Growth Factor-binding Protein-5 Gene Transcription in Human Osteoblasts Is Mediated by a CACCC Sequence in the Proximal Promoter J. Biol. Chem., September 10, 1999; 274(37): 26431 - 26438. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. W. Gregory, D. Kim, P. Ye, A. J. DErcole, T. G. Pretlow, J. L. Mohler, and F. S. French Androgen Receptor Up-Regulates Insulin-Like Growth Factor Binding Protein-5 (IGFBP-5) Expression in a Human Prostate Cancer Xenograft Endocrinology, May 1, 1999; 140(5): 2372 - 2381. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |